focus -WSS

focus

author：leisure time 2025-10-01 17:20:32 - browse：36

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

WSS

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Clinical trials giant ICON acquires HumanFirst

Having children helps parents live longer, especially after age 80

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Kenai launches with $82 million for Parkinson’s stem cell therapy

Pfizer highlights cancer drugs it thinks could reignite investor interest

focus

focus

hotspot

New air purifier tech could be key to improving indoor air quality

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Affirmative action in medical school literally saved lives

FogPharma raises $145 million in rare Series E round

United colonoscopy coverage change 'may cost lives,' doctors say

Resistance to opioid

Supreme Court strikes down use of affirmative action

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Amylyx, Aurinia, and IQVIA

entertainment

Kenai launches with $82 million for Parkinson’s stem cell therapy

Study gives hint on South Asians’ higher risk of cardiovascular disease

FDA does about

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Congress might make insulin pumps more accessible to the blind

Why Eli Lilly’s earnings didn’t quite live up to the hype

focus

focus

Wikipedia

Wikipedia